Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S2.48
P/E—
Fwd P/E9.57
PEG2.72
52W— – —
RSI—
Target$28.88 (+4.2%)
Beta0.30
Div6.22%
Loading chart…
RSI ()
Loading patterns…
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 53
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
4Bearish
0Neutral
Key Signals 1
▼ Double Top
Major reversal
2026-06-18 · $24.84
Two peaks ~$26.05 — bearish reversal confirmed
Learn more →
Momentum Signals 7
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
▲ Bull Flag
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$28.88
+4.2% upside
Low $25
—
High $35
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
74.72%Last 12 Months
Operating Margin
27.88%Last 12 Months
Return on Equity
5.01%Last 12 Months
Revenue Growth
2.60%Year over Year
Free Cash Flow
12.49BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
74.25Most Recent Quarter
Current Ratio
1.27Most Recent Quarter
Cash
11.70BMost Recent Quarter
Total Debt
63.48BMost Recent Quarter
Net Debt
—Most Recent Quarter
How PFE Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 157.99B |
| Enterprise Value | 210.07B |
| Trailing P/E | 36.47 |
| Forward P/E | 9.57 |
| PEG Ratio (5yr) | 2.72 |
| Price/Sales (ttm) | 2.48 |
| Price/Book (mrq) | 1.85 |
| EV/Revenue | 3.30 |
| EV/EBITDA | 8.28 |
Share Statistics
| Avg Vol (3m) | 41.98M |
| Shares Outstanding | 5.70B |
| Float | 5.69B |
| % Held by Insiders | 0.10% |
| % Held by Institutions | 69.12% |
| Short Ratio | 3.91 |
| Short % of Float | 2.66% |
Profitability
| Gross Margin | 74.72% |
| Operating Margin (ttm) | 27.88% |
| Profit Margin | 6.80% |
| Return on Assets (ttm) | 5.78% |
| Return on Equity (ttm) | 5.01% |
Income Statement
| Revenue (ttm) | 63.70B |
| Revenue Growth (yoy) | 2.60% |
| Gross Profit (ttm) | 47.59B |
| EBITDA | 25.38B |
| Net Income (ttm) | 4.34B |
| Diluted EPS (ttm) | 0.76 |
| EPS Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.70B |
| Total Debt (mrq) | 63.48B |
| Debt / Equity (mrq) | 74.25 |
| Current Ratio (mrq) | 1.27 |
| Book Value / Share | 14.95 |
| Operating CF (ttm) | 13.40B |
| Free Cash Flow (ttm) | 12.49B |
Trading & Dividends
| Beta (5Y) | 0.30 |
| 50-Day MA | 26.19 |
| 200-Day MA | 26.21 |
| Fwd Dividend Yield | 6.22% |
| Payout Ratio | 226.32% |
Income
Dividend Yield
6.22%Last 12 Months
Annual Rate
1.72Forward
Payout Ratio
226.32%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 226.32%
Monthly Dividends
Ownership Breakdown
Institutional 69.12%
Insider 0.10%
Public 30.8%
Short Interest
2.66% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in PFE in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|